Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MOS 118

Next Previous
Drug Profile

MOS 118

Alternative Names: AVE-0118; MOS-118

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Antiarrhythmics; Small molecules
  • Mechanism of Action Potassium channel antagonists; Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sleep apnoea syndrome
  • Discontinued Atrial fibrillation; Ventricular fibrillation

Most Recent Events

  • 11 Apr 2023 Mosanna Therapeutics announces intention to submit IND for sleep apnoea syndrome by the end of 2023
  • 11 Apr 2023 Mosanna Therapeutics plans a phase Ib trial for sleep apnoea syndrome by early 2024
  • 19 Jul 2022 MOS 118 is still in phase-I trials for Sleep-apnoea-syndrome in France
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top